Abstract
Objectives. Mycophenolate mofetil (MMF) is used as one of the standard induction/maintenance protocols for lupus nephritis (LN). However, MMF has not been approved for treating LN in any country, resulting in worldwide off-label use of this immunosuppressant. In order to clarify the real-world use of MMF as a treatment for LN in Japan, Japan College of Rheumatology surveyed the use of MMF in daily clinical practice. Methods. Adult patients with LN who visited enrolled hospitals from October 2008 to September 2013 were surveyed for the initial, maximum, and maintenance doses of MMF. The safety and efficacy of MMF were retrospectively evaluated. Results. One hundred and thirty-seven LN patients including 116 females were enrolled. The median of initial, maximum, and maintenance doses of MMF were 1.0 g/day, 1.5 g/day, and 1.0 g/day, respectively. Sixty-one adverse events were reported in 39 patients during the follow-up period. Median urine protein level decreased from 1.89 g/gCr to 0.21 g/gCr, meanC3 level increased from 66.4 mg/dl to 80.3 mg/dl, and median anti-DNA antibody titer decreased from 40.6 IU/ml to 10.6 IU/ml. Conclusion. MMF was commonly used for the treatment of adult LN patients with acceptable efficacy and safety in Japan.
| Original language | English |
|---|---|
| Pages (from-to) | 854-857 |
| Number of pages | 4 |
| Journal | Modern Rheumatology |
| Volume | 25 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Sep 8 2015 |
Fingerprint
Keywords
- Induction therapy
- Mycophenolate mofetil
- Mycophenolic acid
- Proliferative lupus nephritis
- Systemic lupus erythematosus
ASJC Scopus subject areas
- Rheumatology
Cite this
Surveillance for the use of mycophenolate mofetil for adult patients with lupus nephritis in Japan. / Yasuda, Shinsuke; Atsumi, Tatsuya; Shimamura, Sanae; Ono, Kota; Hiromura, Keiju; Sada, Kenei; Mori, Masaaki; Takei, Syuji; Kawaguchi, Yasushi; Tamura, Naoto; Takasaki, Yoshinari.
In: Modern Rheumatology, Vol. 25, No. 6, 08.09.2015, p. 854-857.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Surveillance for the use of mycophenolate mofetil for adult patients with lupus nephritis in Japan
AU - Yasuda, Shinsuke
AU - Atsumi, Tatsuya
AU - Shimamura, Sanae
AU - Ono, Kota
AU - Hiromura, Keiju
AU - Sada, Kenei
AU - Mori, Masaaki
AU - Takei, Syuji
AU - Kawaguchi, Yasushi
AU - Tamura, Naoto
AU - Takasaki, Yoshinari
PY - 2015/9/8
Y1 - 2015/9/8
N2 - Objectives. Mycophenolate mofetil (MMF) is used as one of the standard induction/maintenance protocols for lupus nephritis (LN). However, MMF has not been approved for treating LN in any country, resulting in worldwide off-label use of this immunosuppressant. In order to clarify the real-world use of MMF as a treatment for LN in Japan, Japan College of Rheumatology surveyed the use of MMF in daily clinical practice. Methods. Adult patients with LN who visited enrolled hospitals from October 2008 to September 2013 were surveyed for the initial, maximum, and maintenance doses of MMF. The safety and efficacy of MMF were retrospectively evaluated. Results. One hundred and thirty-seven LN patients including 116 females were enrolled. The median of initial, maximum, and maintenance doses of MMF were 1.0 g/day, 1.5 g/day, and 1.0 g/day, respectively. Sixty-one adverse events were reported in 39 patients during the follow-up period. Median urine protein level decreased from 1.89 g/gCr to 0.21 g/gCr, meanC3 level increased from 66.4 mg/dl to 80.3 mg/dl, and median anti-DNA antibody titer decreased from 40.6 IU/ml to 10.6 IU/ml. Conclusion. MMF was commonly used for the treatment of adult LN patients with acceptable efficacy and safety in Japan.
AB - Objectives. Mycophenolate mofetil (MMF) is used as one of the standard induction/maintenance protocols for lupus nephritis (LN). However, MMF has not been approved for treating LN in any country, resulting in worldwide off-label use of this immunosuppressant. In order to clarify the real-world use of MMF as a treatment for LN in Japan, Japan College of Rheumatology surveyed the use of MMF in daily clinical practice. Methods. Adult patients with LN who visited enrolled hospitals from October 2008 to September 2013 were surveyed for the initial, maximum, and maintenance doses of MMF. The safety and efficacy of MMF were retrospectively evaluated. Results. One hundred and thirty-seven LN patients including 116 females were enrolled. The median of initial, maximum, and maintenance doses of MMF were 1.0 g/day, 1.5 g/day, and 1.0 g/day, respectively. Sixty-one adverse events were reported in 39 patients during the follow-up period. Median urine protein level decreased from 1.89 g/gCr to 0.21 g/gCr, meanC3 level increased from 66.4 mg/dl to 80.3 mg/dl, and median anti-DNA antibody titer decreased from 40.6 IU/ml to 10.6 IU/ml. Conclusion. MMF was commonly used for the treatment of adult LN patients with acceptable efficacy and safety in Japan.
KW - Induction therapy
KW - Mycophenolate mofetil
KW - Mycophenolic acid
KW - Proliferative lupus nephritis
KW - Systemic lupus erythematosus
UR - http://www.scopus.com/inward/record.url?scp=84946838972&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84946838972&partnerID=8YFLogxK
U2 - 10.3109/14397595.2015.1031444
DO - 10.3109/14397595.2015.1031444
M3 - Article
VL - 25
SP - 854
EP - 857
JO - Modern Rheumatology
JF - Modern Rheumatology
SN - 1439-7595
IS - 6
ER -